From: Etiology and management of hypertension in patients with cancer
VEGF inhibitors | TKI | Proteosome inhibitors | Alkylating agents | Miscellaneous |
---|---|---|---|---|
Bevacizumab | Sorafenib | Bortezomib | Cyclophosphamide | Steroids |
Ramucirumab | Sunitinib | Carfilzomib | Ifosfamide | Abiraterone |
Aflibercept | Lenvatinib | Ixazomib | Busulfan | Recombinant human erythropoietin |
Axitinib | Â | Cisplatin | Cyclosporin | |
Ibrutinib | Â | Â | Tacrolimus | |
Cabozantinib | Â | Â | Paclitaxel | |
Pazopanib | Â | Â | Copanlisib | |
Nintedanib | Â | Â | Daratumumab | |
Regorafinib | Â | Â | Elotuzumab |